Comment on

• Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.

  Goláň L, Goker-Alpan O, Holida M, Kantola I, Klopotowski M, Kuusisto J, Linhart A, Musial J, Nicholls K, Gonzalez-Rodriguez D, Sharma R, Vujkovac B, Chang P, Wijatyk A. Goláň L, et al. Drug Des Devel Ther. 2015 Jul 8;9:3435-44. doi: 10.2147/DDDT.S80928. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26185417 Free PMC article. Clinical Trial.
• Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered.

  Ortiz A, Sanchez-Niño MD. Ortiz A, et al. Drug Des Devel Ther. 2015 Nov 2;9:5873-4. doi: 10.2147/DDDT.S93371. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26586938 Free PMC article. No abstract available.